Interpretation of p16INK4a/Ki-67 dual immunostaining for the triage of human papillomavirus-positive women by experts and nonexperts in cervical cytology

Cancer Cytopathology

Volumn 123, Issue 4, 2015, Pages 212-218

  Allia, Elena ^a   Ronco, Guglielmo ^b   Coccia, Anna ^a   Luparia, Patrizia ^a   MacRì, Luigia ^a   Fiorito, Corinna ^c   Maletta, Francesca ^d   Deambrogio, Cristina ^d   Tunesi, Sara ^b,e   De Marco, Laura ^a,f   Gillio Tos, Anna ^a,f   Sapino, Anna ^a,d   Ghiringhello, Bruno ^c  

^a CITTÀ DELLA SALUTE E DELLA SCIENZA HOSPITAL   (Italy)

^b Unit of Cancer Epidemiology   (Italy)

^c S ANNA HOSPITAL   (Italy)

^d UNIVERSITY OF TURIN   (Italy)

^e UNIVERSITY OF EASTERN PIEDMONT   (Italy)

^f UNIVERSITY OF TURIN   (Italy)

Author keywords

cervical cancer; human papillomavirus (HPV) positive women; interpretation; p16INK4a Ki 67; readers

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR 2A; KI 67 ANTIGEN;

ADULT; ARTICLE; CANCER SCREENING; COLPOSCOPY; FEMALE; HUMAN; HUMAN PAPILLOMAVIRUS DNA TEST; IMMUNOHISTOCHEMISTRY; ITALY; MEDICAL EXPERT; PAPANICOLAOU TEST; PAPILLOMAVIRUS INFECTION; PATHOLOGIST; PRIORITY JOURNAL; REPRODUCIBILITY; SENSITIVITY AND SPECIFICITY; UTERINE CERVIX CARCINOMA IN SITU; UTERINE CERVIX CYTOLOGY; COMPARATIVE STUDY; CONTROLLED STUDY; CYTODIAGNOSIS; EARLY DIAGNOSIS; EMERGENCY HEALTH SERVICE; EXPERT WITNESS; METABOLISM; MIDDLE AGED; OBSERVER VARIATION; PAPILLOMAVIRUS INFECTIONS; PATHOLOGY; PILOT STUDY; PROCEDURES; RANDOMIZED CONTROLLED TRIAL; UTERINE CERVICAL NEOPLASMS; UTERINE CERVIX;

ADULT; CERVIX UTERI; CYCLIN-DEPENDENT KINASE INHIBITOR P16; CYTODIAGNOSIS; EARLY DETECTION OF CANCER; EXPERT TESTIMONY; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KI-67 ANTIGEN; MIDDLE AGED; OBSERVER VARIATION; PAPILLOMAVIRUS INFECTIONS; PILOT PROJECTS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; TRIAGE; UTERINE CERVICAL NEOPLASMS;

EID: 84937549435     PISSN: 1934662X     EISSN: 19346638     Source Type: Journal    
DOI: 10.1002/cncy.21511     Document Type: Article

References (25)

1. Naucler P, Ryd W, Tornberg S, et al., Human papillomavirus and Papanicolaou tests to screen for cervical cancer. N Engl J Med. 2007; 357: 1589-1597.
2. Kitchener HC, Almonte M, Thomson C, et al., HPV testing in combination with liquid-based cytology in primary cervical screening (ARTISTIC): a randomised controlled trial. Lancet Oncol. 2009; 10: 672-682.
3. Rijkaart DC, Berkhof J, Rozendaal L, et al., Human papillomavirus testing for the detection of high-grade cervical intraepithelial neoplasia and cancer: final results of the POBASCAM randomised controlled trial. Lancet Oncol. 2012; 13: 78-88.
4. Ronco G, Giorgi-Rossi P, Carozzi F, et al., Efficacy of human papillomavirus testing for the detection of invasive cervical cancers and cervical intraepithelial neoplasia: a randomised controlled trial. Lancet Oncol. 2010; 11: 249-257.
5. Sankaranarayanan R, Nene BM, Shastri SS, et al., HPV screening for cervical cancer in rural India. N Engl J Med. 2009; 360: 1385-1394.
6. Ronco G, Dillner J, Elfstrom M, et al., Efficacy of HPV-based screening for prevention of invasive cervical cancer: follow-up of four European randomised controlled trials. Lancet. 2014; 383: 524-532.
7. von Knebel Doeberitz M., New markers for cervical dysplasia to visualize the genomic chaos created by aberrant oncogenic papillomavirus infections. Eur J Cancer. 2002; 38: 2229-2242.
8. Wentzensen N, von Knebel Doeberitz M., Biomarkers in cervical cancer screening. Dis Markers. 2007; 23: 315-330.
9. Klaes R, Friedrich T, Spitkovsky D, et al., Overexpression of p16(INK4A) as a specific marker for dysplastic and neoplastic epithelial cells of the cervix uteri. Int J Cancer. 2001; 92: 276-284.
10. Sano T, Oyama T, Kashiwabara K, Fukuda T, Nakajima T., Expression status of p16 protein is associated with human papillomavirus oncogenic potential in cervical and genital lesions. Am J Pathol. 1998; 153: 1741-1748.
11. INK4a immunochemistry in cervical histopathology and cytology: an update of recent developments [published online ahead of print April 17, 2014]. Int J Cancer. doi: 10.1002/ijc.28900.
12. Carozzi F, Confortini M, Dalla Palma P, et al,; New Technologies for Cervical Cancer Screening (NTCC) Working Group. Use of p16-INK4A overexpression to increase the specificity of human papillomavirus testing: a nested substudy of the NTCC randomised controlled trial. Lancet Oncol. 2008; 9: 937-945.
13. Carozzi F, Gillio-Tos A, Confortini M, et al,; NTCC Working Group. Risk of high-grade cervical intraepithelial neoplasia during follow-up in HPV-positive women according to baseline p16-INK4A results: a prospective analysis of a nested substudy of the NTCC randomised controlled trial. Lancet Oncol. 2013; 14: 168-176.
14. INK4a positive cells to identify patients with high-grade cervical intraepithelial neoplasia. Cancer. 2007; 111: 58-66.
15. INK4a-stained cervical squamous cells in liquid-based cytology samples. Cancer. 2005; 105: 461-467.
16. INK4a) immunostaining in cytological and histological specimens from the uterine cervix: a systematic review and meta-analysis. Cancer Treat Rev. 2009; 35: 210-220.
17. Heatley MK., Ki67 protein: the immaculate deception? Histopathology. 2002; 40: 483.
18. Scholzen T, Gerdes J., The Ki-67 protein: from the known and the unknown. J Cell Physiol. 2000; 182: 311-322.
19. Fleiss JL., Statistical Methods for Rates and Proportions. 2nd ed. New York: John Wiley & Sons; 1981.
20. Lee J, Fung KP., Confidence interval of the kappa coefficient by bootstrap resampling. Psychiatry Res. 1993; 49: 97-98.
21. Ronco G, Biggeri A., Estimating sensitivity and specificity when repeated tests are performed on the same subject. J Epidemiol Biostat. 1999; 4: 329-336.
22. Coughlin SS, Trock B, Criqui MH, Pickle LW, Browner D, Tefft MC., The logistic modelling of sensitivity, specificity, and predictive value of a diagnostic test. J Clin Epidemiol. 1992; 45: 1-7.
23. Zeger SL, Liang KY., An overview of methods for the analysis of longitudinal data. Stat Med. 1992; 11: 1825-1839.
24. Wentzensen N, Fetterman B, Tokugawa D, et al., Interobserver reproducibility and accuracy of p16/Ki-67 dual-stain cytology in cervical cancer screening [published online ahead of print August 12, 2014]. Cancer (Cancer Cytopathol). doi: 10.1002/cncy.21473.
25. Ikenberg H, Bergeron C, Schmidt D, et al,; PALMS Study Group. Screening for cervical cancer precursors with p16/Ki-67 dual-stained cytology: results of the PALMS study. J Natl Cancer Inst. 2013; 105: 1550-1557.